348 related articles for article (PubMed ID: 18537607)
1. Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.
Leone G; D'Alò F; Zardo G; Voso MT; Nervi C
Curr Med Chem; 2008; 15(13):1274-87. PubMed ID: 18537607
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic deregulation in myeloid malignancies.
Meldi KM; Figueroa ME
Transl Res; 2015 Jan; 165(1):102-14. PubMed ID: 24813528
[TBL] [Abstract][Full Text] [Related]
3. The DAC system and associations with acute leukemias and myelodysplastic syndromes.
Bug G; Ottmann OG
Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S36-49. PubMed ID: 21153858
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic manipulation of the immune response: a novel treatment strategy in hematologic malignancies.
Craddock C
Cytotherapy; 2011 May; 13(5):516-7. PubMed ID: 21375421
[No Abstract] [Full Text] [Related]
5. Epigenetic changes in the myelodysplastic syndrome.
Issa JP
Hematol Oncol Clin North Am; 2010 Apr; 24(2):317-30. PubMed ID: 20359628
[TBL] [Abstract][Full Text] [Related]
6. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Lowder JN; Taverna P; Issa JP
Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
[No Abstract] [Full Text] [Related]
7. Epigenetic therapies move into new territory, but how exactly do they work?
Tuma RS
J Natl Cancer Inst; 2009 Oct; 101(19):1300-1. PubMed ID: 19755677
[No Abstract] [Full Text] [Related]
8. Clinical development of demethylating agents in hematology.
Navada SC; Steinmann J; Lübbert M; Silverman LR
J Clin Invest; 2014 Jan; 124(1):40-6. PubMed ID: 24382388
[TBL] [Abstract][Full Text] [Related]
9. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
10. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
Figueroa ME; Skrabanek L; Li Y; Jiemjit A; Fandy TE; Paietta E; Fernandez H; Tallman MS; Greally JM; Carraway H; Licht JD; Gore SD; Melnick A
Blood; 2009 Oct; 114(16):3448-58. PubMed ID: 19652201
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML.
Botezatu L; Michel LC; Helness A; Vadnais C; Makishima H; Hönes JM; Robert F; Vassen L; Thivakaran A; Al-Matary Y; Lams RF; Schütte J; Giebel B; Görgens A; Heuser M; Medyouf H; Maciejewski J; Dührsen U; Möröy T; Khandanpour C
Exp Hematol; 2016 Aug; 44(8):713-726.e14. PubMed ID: 27216773
[TBL] [Abstract][Full Text] [Related]
12. Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents.
Santini V; Melnick A; Maciejewski JP; Duprez E; Nervi C; Cocco L; Ford KG; Mufti G
Crit Rev Oncol Hematol; 2013 Nov; 88(2):231-45. PubMed ID: 23838480
[TBL] [Abstract][Full Text] [Related]
13. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Gore SD; Baylin S; Sugar E; Carraway H; Miller CB; Carducci M; Grever M; Galm O; Dauses T; Karp JE; Rudek MA; Zhao M; Smith BD; Manning J; Jiemjit A; Dover G; Mays A; Zwiebel J; Murgo A; Weng LJ; Herman JG
Cancer Res; 2006 Jun; 66(12):6361-9. PubMed ID: 16778214
[TBL] [Abstract][Full Text] [Related]
14. Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.
Lübbert M; Kuendgen A
Cancer; 2015 Feb; 121(4):498-501. PubMed ID: 25336205
[No Abstract] [Full Text] [Related]
15. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Griffiths EA; Gore SD
Semin Hematol; 2008 Jan; 45(1):23-30. PubMed ID: 18179966
[TBL] [Abstract][Full Text] [Related]
16. Improving the outlook for myelodysplastic syndrome.
Brower V
J Natl Cancer Inst; 2012 Aug; 104(16):1204-6. PubMed ID: 22899627
[No Abstract] [Full Text] [Related]
17. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
[TBL] [Abstract][Full Text] [Related]
18. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.
Khan H; Vale C; Bhagat T; Verma A
Semin Hematol; 2013 Jan; 50(1):16-37. PubMed ID: 23507481
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic therapies in MDS and AML.
Griffiths EA; Gore SD
Adv Exp Med Biol; 2013; 754():253-83. PubMed ID: 22956506
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 1):1-10; quiz 11-2. PubMed ID: 21438190
[No Abstract] [Full Text] [Related]
[Next] [New Search]